Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
BMC Public Health|April 8, 2020
The costs of treating vaginal and vulval cancer in England (2009-2015)Stephanie Stephens, Anuja Chatterjee, Victoria Coles, et al.Global & Regional Health Technology Assessment|October 9, 2023
Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2-, node-positive, high-risk early breast cancer in ItalyAlison Davie, Sory Traoré, Massimo Giovannitti, et al.Antimicrobial Resistance and Infection Control|May 2, 2018
Estimating the burden of antimicrobial resistance: a systematic literature reviewNichola R Naylor, Rifat Atun, Nina Zhu, et al.Systematic Reviews|December 13, 2017
Investigating the burden of antibiotic resistance in ethnic minority groups in high-income countries: protocol for a systematic review and meta-analysisHannah Lishman, Paul Aylin, Vivian Alividza, et al.Journal of Managed Care & Specialty Pharmacy|October 29, 2021
Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United StatesAnuja Chatterjee, Sheila Shapouri, Beenish S Manzoor, et al.Pharmacoeconomics - Open|November 5, 2022
A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in CanadaAnuja Chatterjee, Gijs van de Wetering, Ron Goeree, et al.One Health (Amsterdam, Netherlands)|March 3, 2025
Mapping socioeconomic factors driving antimicrobial resistance in humans: An umbrella reviewGunnar Ljungqvist, Robin van Kessel, Elias Mossialos, et al.The Lancet. Infectious Diseases|September 3, 2018
Quantifying drivers of antibiotic resistance in humans: a systematic reviewAnuja Chatterjee, Maryam Modarai, Nichola R Naylor, et al.Pageof 1